Schering AG, Germany’s U.S. affiliate Berlex, Inc. just announced the USFDA approval of Yaz® (3 mg drospirenone/20 mcg ethinyl estradiol), a new monophasic oral contraceptive (OC) and the first pill to combine 20 mcg of ethinyl estradiol with the innovative progestin drospirenone (drsp). Yaz®, a 24-day active hormone pill with less hormonal fluctuation than traditional OCs that provide 21 days of active pills will be available by prescription in the U.S. next month
"YAZ represents a clear advancement in oral contraception, and underscores the Berlex commitment to provide novel and innovative options in birth control to allow for individual choice," said Reinhard Franzen, President and CEO of Berlex Laboratories. "We are continuing our dialogue with the FDA in order to take YAZ even further by bringing women the first oral contraceptive for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder, or PMDD."
Read the complete report.
.jpg)
Comment Preview